written on 19.05.2014

Valeant's $47B Allergan buyout could spawn a breakup, CEO tells investors


Valeant&#39;s $47 billion bid to buy eye-drug giant Allergan is far from a done deal, but that isn&#39;t stopping Valeant&#39;s management team from making big promises to investors about what might happen after the acquisition. While briefing a few of Allergan&#39;s largest investors, Valeant&#39;s top brass said it would consider splitting up the company if it became too big to support its aggressive M&amp;A strategy, according to <em>Reuters</em>.